Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mirati Therapeutics
Pharma
BMS details Krazati confirmatory fail in colorectal cancer
BMS has detailed a phase 3 flop for KRAS inhibitor Krazati's smaller-opportunity accelerated FDA approval in colorectal cancer.
Fraiser Kansteiner
Jul 7, 2026 10:46am
FDA blasts Bristol Myers over misleading Krazati efficacy claims
Aug 8, 2024 10:59am
BMS and Mirati's KRAS inhibitor Krazati moves beyond NSLC
Jun 24, 2024 8:53am
BMS' dealmaking appetite remains intact, CEO says
Jun 12, 2024 10:55am
BMS cuts hundreds of Mirati staffers shortly after buyout
Mar 26, 2024 5:25pm
BMS says goodbye to its top dealmaker Elizabeth Mily
Dec 8, 2023 11:25am
